IRADIMED CORPORATION (IRMD) News
Track canonical SquawkNews coverage tagged to IRMD, IRADIMED CORPORATION. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Raises FY2026 Sales Guidance from $91.000M-$96.000M to
iRadimed (NASDAQ: IRMD ) raises FY2026 Adj EPS guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 analyst estimate. Raises FY2026 sales outlook from $91.000 million-$96.000 million to $91.000 billion-$96.000 billion vs $9
EARNINGS | Jul 31, 2026, 12:16 PM UTC
L
IRMD Iradimed RESULTS: Q2, Q2 REV $20.5M, Q2 EPS $0.41
IRMD Iradimed RESULTS: Q2, Q2 REV $20.5M, Q2 EPS $0.41
EARNINGS | Jul 31, 2026, 12:15 PM UTC
L
IRMD - IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
IRMD - IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 31, 2026, 12:15 PM UTC
L
Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline
Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline
EQUITY | Jul 27, 2026, 02:10 PM UTC